ArticleBMC pediatrics2026
Predictive value of FeNO, eosinophils, and IgE for airway hyperresponsiveness in children with chronic cough: a cross-sectional study.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo investigate the clinical characteristics of children with chronic cough and to evaluate the predictive value of fractional exhaled nitric oxide (FeNO), peripheral blood eosinophil (EOS) count, and total immunoglobulin E (IgE) for airway hyperresponsiveness (AHR).
methodsThis retrospective, cross-sectional study included 142 children with chronic cough who underwent bronchial provocation testing (BPT) at the Children’s Hospital of Hebei Province between September 2024 and August 2025. Based on BPT results, participants were divided into an AHR-positive group (n = 119) and an AHR-negative group (n = 23). We compared clinical features, pulmonary function parameters, FeNO levels, EOS counts, and total IgE levels between the two groups. Receiver operating characteristic (ROC) curves were generated to assess the predictive performance of FeNO, EOS, and IgE for AHR, including pairwise and triple combinations.
resultsThe AHR-positive group exhibited a significantly higher prevalence of nocturnal cough (68.9% vs. 26.1%, P < 0.001), eczema/urticaria (68.1% vs. 34.8%, P = 0.004), allergic rhinitis (66.4% vs. 34.8%, P = 0.006), and allergic conjunctivitis (68.1% vs. 21.7%, P < 0.001) compared to the AHR-negative group. Patients with AHR had significantly lower small airway function parameters, including FEF75%pred (Median: 64.5% vs. 74.1%, P = 0.038) and FEF25%-75%pred (Median: 66.6% vs. 86.5%, P < 0.001). Furthermore, FeNO (Median: 27.3 vs. 19.0 ppb, P = 0.022), EOS count (Median: 0.35 vs. 0.19 × 10⁹/L, P = 0.045), and total IgE levels (Median: 262.1 vs. 121.1 IU/mL, P < 0.001) were all significantly elevated in the AHR-positive group. ROC analysis showed that total IgE had the best individual predictive value (AUC: 0.724), followed by FeNO (AUC: 0.651) and EOS (AUC: 0.632). A combined model incorporating all three biomarkers demonstrated superior predictive accuracy (AUC: 0.852). Significant negative correlations were observed between AHR severity and levels of FeNO and IgE.
conclusionChildren with chronic cough and AHR present distinct clinical and physiological profiles characterized by atopic comorbidities, small airway dysfunction, and elevated type 2 inflammatory biomarkers. The combined assessment of FeNO, EOS, and IgE offers significant clinical value as a non-invasive screening tool for predicting AHR in this population, potentially guiding risk stratification in settings where BPT is not readily accessible. Further external validation is required before routine clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.